Kyowa Kirin

Kyowa Kirin KYKOF Stock

$16.45   0.920255%
Add to favorites
Market Cap
$8.61B
LOW - HIGH [24H]
$16.45 - $16.75
VOLUME [24H]
$1.01K
P/E Ratio
16.28
Earnings per share
$1.01
ISIN
JP3256000005
Price   Prediction

Kyowa Kirin Price Chart

Sorry, that's all we've gotfor now...

Kyowa Kirin (KYKOF) stock price today is 16.45 USD on OTC Markets OTCPK (+0.92% on the day). Updated .

Kyowa Kirin KYKOF Financial and Trading Overview

Kyowa Kirin stock price 16.45 USD
Previous Close 16.3 USD
Open 16.45 USD
Bid 15.81 USD x 10000
Ask 16.52 USD x 10000
Day's Range 16.45 - 16.75 USD
52 Week Range 4.2 - 18 USD
Volume 1.01K USD
Avg. Volume 4.32K USD
Market Cap 8.77B USD
Beta (5Y Monthly) 0.22
PE Ratio (TTM) 16.584158
EPS (TTM) 1.01 USD
Forward Dividend & Yield 0.44 (2.68%)
Ex-Dividend Date December 29, 2026
1y Target Est N/A

KYKOF Valuation Measures

Enterprise Value -232501035008 USD
Trailing P/E 16.584158
Forward P/E 17.447918
PEG Ratio (5 yr expected) 4.64
Price/Sales (ttm) 0.01647513
Price/Book (mrq) 1.5266275
Enterprise Value/Revenue -0.437
Enterprise Value/EBITDA -1.845

Trading Information

Kyowa Kirin Stock Price History

Beta (5Y Monthly) 0.22
52-Week Change 1.30%
S&P500 52-Week Change 13.32%
52 Week High 18 USD
52 Week Low 4.2 USD
50-Day Moving Average 15.18 USD
200-Day Moving Average 14.63 USD

KYKOF Share Statistics

Avg. Volume (3 month) 4.32K USD
Avg. Daily Volume (10-Days) 1.8K USD
Shares Outstanding 523.59M
Float 234.48M
Short Ratio N/A
% Held by Insiders 55.72%
% Held by Institutions 18.98%
Shares Short N/A
Short % of Float N/A
Short % of Shares Outstanding N/A

Dividends & Splits

Trailing Annual Dividend Rate 67
Trailing Annual Dividend Yield 411.04%
5 Year Average Dividend Yield 208.00%
Payout Ratio 0.4312
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 16.17%
Operating Margin (ttm) 17.94%
Gross Margin 74.74%
EBITDA Margin 23.67%

Management Effectiveness

Return on Assets (ttm) 5.51%
Return on Equity (ttm) 9.81%

Income Statement

Revenue (ttm) 532.32B USD
Revenue Per Share (ttm) 1016.79 USD
Quarterly Revenue Growth (yoy) 2.10%
Gross Profit (ttm) 397.87B USD
EBITDA 126.01B USD
Net Income Avi to Common (ttm) 86.11B USD
Diluted EPS (ttm) 1.01
Quarterly Earnings Growth (yoy) 29.29%

Balance Sheet

Total Cash (mrq) 241.11B USD
Total Cash Per Share (mrq) 460.51 USD
Total Debt (mrq) 0 USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 3.211
Book Value Per Share (mrq) 10.971897

Cash Flow Statement

Operating Cash Flow (ttm) 113.29B USD
Levered Free Cash Flow (ttm) -12835999744 USD

Profile of Kyowa Kirin

Country United States
State N/A
City Chiyoda
Address Otemachi Financial City Grand Cube
ZIP 100-0004
Phone 81 3 5205 7200
Website https://www.kyowakirin.com
Industry Drug Manufacturers - Specialty & Generic
Sector(s) Healthcare
Full Time Employees 5161

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.

Q&A For Kyowa Kirin Stock

What is a current KYKOF stock price?

Kyowa Kirin KYKOF stock price today per share is 16.45 USD.

How to purchase Kyowa Kirin stock?

You can buy KYKOF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Kyowa Kirin?

The stock symbol or ticker of Kyowa Kirin is KYKOF.

Which industry does the Kyowa Kirin company belong to?

The Kyowa Kirin industry is Drug Manufacturers - Specialty & Generic.

How many shares does Kyowa Kirin have in circulation?

The max supply of Kyowa Kirin shares is 523.59M.

What is Kyowa Kirin Price to Earnings Ratio (PE Ratio)?

Kyowa Kirin PE Ratio is 16.28713000 now.

What was Kyowa Kirin earnings per share over the trailing 12 months (TTM)?

Kyowa Kirin EPS is 1.01 USD over the trailing 12 months.

Which sector does the Kyowa Kirin company belong to?

The Kyowa Kirin sector is Healthcare.

$2.19T
Total marketcap
$78.03B
Total volume
BTC 58.32%   •   ETH 9.91%
Dominance
Select currency